Shallow whole-genome sequencing of plasma cell-free DNA accurately differentiates small from non-small cell lung carcinoma.
Cell-free DNA
Copy number alterations
Histological classification
Liquid biopsy
Lung cancer
Shallow whole-genome sequencing
Journal
Genome medicine
ISSN: 1756-994X
Titre abrégé: Genome Med
Pays: England
ID NLM: 101475844
Informations de publication
Date de publication:
21 04 2020
21 04 2020
Historique:
received:
06
11
2019
accepted:
07
04
2020
entrez:
23
4
2020
pubmed:
23
4
2020
medline:
5
1
2021
Statut:
epublish
Résumé
Accurate lung cancer classification is crucial to guide therapeutic decisions. However, histological subtyping by pathologists requires tumor tissue-a necessity that is often intrinsically associated with procedural difficulties. The analysis of circulating tumor DNA present in minimal-invasive blood samples, referred to as liquid biopsies, could therefore emerge as an attractive alternative. Concerning adenocarcinoma, squamous cell carcinoma, and small cell carcinoma, our proof of concept study investigates the potential of liquid biopsy-derived copy number alterations, derived from single-end shallow whole-genome sequencing (coverage 0.1-0.5×), across 51 advanced stage lung cancer patients. Genomic abnormality testing reveals anomalies in 86.3% of the liquid biopsies (16/20 for adenocarcinoma, 13/16 for squamous cell, and 15/15 for small cell carcinoma). We demonstrate that copy number profiles from formalin-fixed paraffin-embedded tumor biopsies are well represented by their liquid equivalent. This is especially valid within the small cell carcinoma group, where paired profiles have an average Pearson correlation of 0.86 (95% CI 0.79-0.93). A predictive model trained with public data, derived from 843 tissue biopsies, shows that liquid biopsies exhibit multiple deviations that reflect histological classification. Most notably, distinguishing small from non-small cell lung cancer is characterized by an area under the curve of 0.98 during receiver operating characteristic analysis. Additionally, we investigated how deeper paired-end sequencing, which will eventually become feasible for routine diagnosis, empowers tumor read enrichment by insert size filtering: for all of the 29 resequenced liquid biopsies, the tumor fraction could be increased in silico, thereby "rescuing" three out of five cases with previously undetectable alterations. Copy number profiling of cell-free DNA enables histological classification. Since shallow whole-genome sequencing is inexpensive and often fully operational at routine molecular laboratories, this finding has current diagnostic potential, especially for patients with lesions that are difficult to reach.
Sections du résumé
BACKGROUND
Accurate lung cancer classification is crucial to guide therapeutic decisions. However, histological subtyping by pathologists requires tumor tissue-a necessity that is often intrinsically associated with procedural difficulties. The analysis of circulating tumor DNA present in minimal-invasive blood samples, referred to as liquid biopsies, could therefore emerge as an attractive alternative.
METHODS
Concerning adenocarcinoma, squamous cell carcinoma, and small cell carcinoma, our proof of concept study investigates the potential of liquid biopsy-derived copy number alterations, derived from single-end shallow whole-genome sequencing (coverage 0.1-0.5×), across 51 advanced stage lung cancer patients.
RESULTS
Genomic abnormality testing reveals anomalies in 86.3% of the liquid biopsies (16/20 for adenocarcinoma, 13/16 for squamous cell, and 15/15 for small cell carcinoma). We demonstrate that copy number profiles from formalin-fixed paraffin-embedded tumor biopsies are well represented by their liquid equivalent. This is especially valid within the small cell carcinoma group, where paired profiles have an average Pearson correlation of 0.86 (95% CI 0.79-0.93). A predictive model trained with public data, derived from 843 tissue biopsies, shows that liquid biopsies exhibit multiple deviations that reflect histological classification. Most notably, distinguishing small from non-small cell lung cancer is characterized by an area under the curve of 0.98 during receiver operating characteristic analysis. Additionally, we investigated how deeper paired-end sequencing, which will eventually become feasible for routine diagnosis, empowers tumor read enrichment by insert size filtering: for all of the 29 resequenced liquid biopsies, the tumor fraction could be increased in silico, thereby "rescuing" three out of five cases with previously undetectable alterations.
CONCLUSIONS
Copy number profiling of cell-free DNA enables histological classification. Since shallow whole-genome sequencing is inexpensive and often fully operational at routine molecular laboratories, this finding has current diagnostic potential, especially for patients with lesions that are difficult to reach.
Identifiants
pubmed: 32317009
doi: 10.1186/s13073-020-00735-4
pii: 10.1186/s13073-020-00735-4
pmc: PMC7175544
doi:
Substances chimiques
Cell-Free Nucleic Acids
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
35Références
Cancer Cell. 2017 Aug 14;32(2):238-252.e9
pubmed: 28810146
Oncology. 1974;30(5):353-61
pubmed: 4462059
Nat Commun. 2017 Nov 6;8(1):1324
pubmed: 29109393
Lung Cancer. 2015 Oct;90(1):78-84
pubmed: 26233568
Oncology. 1989;46(5):318-22
pubmed: 2779946
BMC Health Serv Res. 2017 Jan 17;17(1):45
pubmed: 28095840
Arch Pathol Lab Med. 2019 Dec 17;:
pubmed: 31846367
EMBO Mol Med. 2018 Dec;10(12):
pubmed: 30401727
Cancer Manag Res. 2019 Jan 21;11:943-953
pubmed: 30718965
Thorax. 2013 Jun;68(6):551-64
pubmed: 23399908
Nat Commun. 2018 Aug 6;9(1):3114
pubmed: 30082701
J Hematol Oncol. 2019 May 2;12(1):47
pubmed: 31046803
Sci Transl Med. 2018 Nov 7;10(466):
pubmed: 30404863
Nucleic Acids Res. 2019 Feb 28;47(4):1605-1614
pubmed: 30566647
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Nature. 2019 Jun;570(7761):385-389
pubmed: 31142840
Nat Med. 2014 Aug;20(8):897-903
pubmed: 24880617
Clin Cancer Res. 2016 Jul 15;22(14):3618-29
pubmed: 26960398
Genes Chromosomes Cancer. 2017 Jul;56(7):559-569
pubmed: 28379620
Clin Cancer Res. 2017 Oct 15;23(20):6305-6314
pubmed: 28710315
Transl Lung Cancer Res. 2016 Feb;5(1):26-38
pubmed: 26958491
Clin Cancer Res. 2017 Sep 1;23(17):5074-5081
pubmed: 28320758
Nat Methods. 2012 Mar 04;9(4):357-9
pubmed: 22388286
Lung Cancer (Auckl). 2018 Jan 03;9:1-11
pubmed: 29379323
J Clin Oncol. 2008 Jul 20;26(21):3543-51
pubmed: 18506025
Biostatistics. 2004 Oct;5(4):557-72
pubmed: 15475419
J Thorac Dis. 2018 Apr;10(Suppl 7):S882-S897
pubmed: 29780635
Genome Med. 2013 Apr 05;5(4):30
pubmed: 23561577
Sci Transl Med. 2013 Oct 30;5(209):209ra153
pubmed: 24174329
Pharmacol Ther. 2016 Jan;157:120-4
pubmed: 26615782
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Transl Lung Cancer Res. 2015 Feb;4(1):36-54
pubmed: 25806345
Nat Biotechnol. 2016 May;34(5):547-555
pubmed: 27018799
Lancet Oncol. 2015 Apr;16(4):e165-72
pubmed: 25846096
PLoS One. 2014 Feb 05;9(2):e88300
pubmed: 24505469
Oncotarget. 2015 Jun 30;6(18):16411-21
pubmed: 25915538